Chardan Capital Reiterates Buy on Iovance Biotherapeutics, Maintains $29 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a $29 price target.
May 30, 2023 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital reiterated a Buy rating on Iovance Biotherapeutics and maintained a $29 price target.
The reiteration of a Buy rating and maintenance of a $29 price target by Chardan Capital analyst Geulah Livshits indicates a positive outlook for Iovance Biotherapeutics. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100